健帆生物(300529.SZ):血液透析濃縮液取得醫療器械註冊證
格隆匯7月25日丨健帆生物(300529.SZ)公佈,公司之控股子公司天津標準於近日收到國家藥品監督管理局頒發的《醫療器械註冊證》,本次取得註冊證的產品是血液透析濃縮液(高鉀配方),具有糾正電解質紊亂和低鉀血癥等優勢,能滿足血透患者的個性化治療需求。
本次取得註冊證的高鉀配方血液透析濃縮液是公司控股子公司天津標準的新配方、新產品。該配方的主要特點為3.0mmol/L的鉀離子濃度,能夠有效降低維持性血液透析患者血壓下降及心率失常的發生率,糾正電解質紊亂和低鉀血癥,提升血透患者的透析質量。
至此,公司共有高鉀配方透析液、枸櫞酸型透析液/粉、含糖透析液、不同鈣離子濃度透析液等不同品規的血液透析濃縮液/乾粉產品系列,公司血液淨化產品種類進一步得到豐富,能更好地滿足臨牀個性化的治療需求,符合公司深耕血液淨化領域的戰略佈局,將對公司未來的經營發展產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.